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Abstract 
Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided 
by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate 
diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective 
analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers 
from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the 
diagnostic work up of CJD. 
Beside the assessment of relevant clinical data and the findings of electroencephalography and 
brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were 
determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF 
of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at 
the Department of Neurology, University of Szeged. 
This preliminary study provided 100% sensitivity for 14-3-3, and interestingly, only 40% 
specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values 
were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, 
depending on the applied cut-off levels.  
The poor specificity of 14-3-3 is not in line with literature data and may be the result of 
the small number of patients in the cohort with non-prion disease, predominantly 
consisting of disorders with considerable tissue damage, whereas tTau presented good 
sensitivity and specificity values. The combined application of these and novel chemical 
biomarkers may increase both sensitivity and specificity to a desired level. 
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Absztrakt 
Mivel jelenleg csak a pathológiai vizsgálat nyújt biztos diagnózist a Creutzfeldt-Jakob betegség 
(CJB) vonatkozásában, ezért különösen nagy szükség van olyan tesztekre, melyek még élő 
állapotban szolgáltatnak megfelelő diagnózist lehetőleg a betegség kezdeti stádiumában. Jelen 
tanulmány célja egy előzetes retrospektív analízis végzése volt a gyorsan progrediáló 
demenciával diagnosztizált betegek liquor totál tau (tTau) és néhány egyéb biomarker 
szintjének CJB diagnosztikájában való használhatóságáról. 
A releváns klinikai adatok, valamint elektroenkefalográfiás és agyi mágneses magrezonanciás 
vizsgálati eredmények feldolgozása mellett a 14-3-3 fehérje kimutatása, továbbá a tTau szint 
meghatározása Western blot, illetve enzimhez kapcsolt immunoszorbens vizsgálatokkal történt 
19, a Szegedi Tudományegyetem Neurológiai Klinikáján 2004-2017 között gyorsan 
progrediáló demenciával diagnosztizált beteg liquorából. 
A jelen előzetes tanulmány a CJB klinikai diagnózisának megerősítése vonatkozásában 
100%-os szenzitivitást, ugyanakkor meglepő módon, csak 40%-os specificitást mutatott a 14-
3-3 fehérjére. A tTau esetén a szenzitivitás 100%-nak, illetve 83%-nak, míg a specificitás 71%-
nak, illetve 86%-nak adódott a használt referenciaértéktől függően. 
A 14-3-3 jelen tanulmányban kapott alacsony specificitása nem reprezentálja a 
szakirodalomban közölt adatokat, melynek hátterében a nem prion betegségek között a 
jelentős szövetkárosodással társuló kórképek nagyarányú előfordulása állhat, míg a tTau 
egyaránt jó szenzitivitást és specificitást mutatott. Valószínűleg a fenti anyagok és néhány 
új kémiai biomarker együttes alkalmazása a megfelelő szintre emelheti mind a szenzitivitást, 
mind a specificitást a CJB diagnosztikájában.  
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1. Introduction 
Human transmissible spongiform encephalopathies, which include Creutzfeldt-Jakob disease 
(CJD), Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI), and kuru 
are rare neurodegenerative disorders, out of which CJD is by far the most common (1-
2/1.000.000 person/year)1. Beside classic prion diseases, the prion-like propagation of the 
pathological process was raised in other neurodegenerative conditions, such as Alzheimer’s 
disease (AD) and Parkinson’s disease as well2. CJD is characterized by a rapid disease course 
associated with the conformational transformation of the human cellular prion protein (PrPc) 
into the neurotoxic, protease-resistant scrapie form of this protein (PrPSc)3. Considering the 
etiology of CJD, sporadic, familial, and acquired (variant and iatrogenic) forms are specified3,4. 
The sporadic form (sCJD) is the most common type, representing approximately 85% of all 
CJD cases with an unknown mechanism of infection5. It has 6 phenotypes, obtained from the 
combination of the methionine/valine (M/V) polymorphism in the coding region of the prion 
protein gene (PRNP) with the two isoforms of the PrPSc6. The genetic form of CJD (gCJD) 
accounts for 10-15% of the cases internationally7. The variant form of CJD (vCJD) shows a 
regional accumulation, mainly restricted to the United Kingdom and France, and it is known to 
be caused by consuming bovine spongiform encephalopathy-infected food8. The principal 
sources of iatrogenic CJD (iCJD) include contaminated growth hormone extracts and dura 
mater grafts derived from human cadavers with undiagnosed CJD infections, and it has an 
incidence of 1% of all CJD cases9. 
In addition to the presence of characteristic rapidly progressive dementia, the clinical picture 
may include the following clinical features: myoclonus, visual or cerebellar disturbance, 
pyramidal/extrapyramidal dysfunction, and akinetic mutism10,11. Along with the 
demonstration of PrP in certain tissues with real-time quaking-induced conversion (RT-
QuIC) AND/OR typical electroencephalographic (EEG) findings during an illness of any 
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duration AND/OR a positive 14-3-3 cerebrospinal fluid (CSF) assay with a clinical duration to 
death < 2 years AND/OR high signal abnormalities in the caudate nucleus and putamen or at 
least two cortical regions (temporal-parietal-occipital) either in DWI or FLAIR sequences IF 
routine investigations do not suggest an alternative diagnosis, the diagnosis of probable or 
possible CJD can be set up depending on the number of matching factors10–12. The diagnosis of 
definite CJD requires comprehensive post-mortem neuropathological assessment10,11. Although 
the current diagnostic criteria list only 14-3-3 and PrP4 as biomarkers, total tau (tTau), 
phosphorylated tau (pTau), α-synuclein, S100B protein13–16, neuron-specific enolase (NSE)17, 
neurofilament light chain (NF-L)18, phosphorylated neurofilament heavy chain (pNF-H)18, and 
-amyloid peptide (A)19 were also assessed for their suitability as biomarkers (Fig. 1.). 
The presence of 14-3-3 protein in the CSF, which is characteristic of almost 95% of sCJD 
cases17, is currently measured by enzyme-linked immunosorbent assay (ELISA) instead 
of the previously widely applied Western blot method20. From the 7 known isomers (β, γ, ε, 
ζ, η, σ, and τ) only the presence of the β, γ, ε, and η forms has been demonstrated in CJD21. The 
tTau protein proved to be a useful biomarker in the diagnostic work up of different neurological 
diseases, including AD22 and CJD, and together with the presence of 14-3-3 protein, they can 
reliably support the clinical diagnosis13. The tTau protein is highly increased in CJD, whereas 
this characteristic elevation cannot be observed for pTau16,17. In addition to the above-
mentioned proteins, the levels of NF-L and pNF-H were found increased as well in both serum 
and CSF samples18,23. With regard to -amyloid concentrations, similarly to AD, decreased 
values were reported compared to control groups19,24,25. It was demonstrated that S100B protein 
may have a role in the diagnosis of genetic prion diseases, including gCJD, GSS, and FFI, 
showing elevated concentrations beside the presence of the positivity of 14-3-3 and the 
increased level of NSE17. The level of α-synuclein protein, measured by 
electrochemiluminescence-based human ELISA kit, was considerably elevated in sCJD cases 
7 
 
compared to controls15,26. Furthermore, the confirmation of the presence of PrPSc in live patients 
was proposed to be included in the criteria for an in vivo definite diagnosis in the future27. There 
are different techniques for the detection of PrP or PrPSc from different body fluids such 
as CSF, nasal brushing or blood samples20, including the protein misfolding cyclic 
amplification (PMCA) assay, Western blotting, ELISA, RT-QuIC, the amyloid seeding 
assay (ASA), and the PrP aggregate formation assay (PAFA) for the measurement of the 
seeding activity of PrPSc28. 
The measurement of -amyloid peptide 1-42 (A1-42), tTau, and pTau proteins by ELISA 
method is available since 2009 in our institute for scientific purposes. Although the assessment 
of these 3 biomarkers may mainly have a supporting role in the clinical diagnosis of AD, but 
the above data may raise the possibility of the usefulness of particularly tTau protein in the 
diagnostic work up of CJD as well. 
The aim of the present preliminary retrospective study was to measure the levels of tTau, pTau, 
and A1-42 in the CSF samples of our patients with the presumptive clinical diagnosis of CJD 
from 2004 to 2017, and to assess their potential supporting diagnostic role in the context of 
other available test results (such as EEG, brain magnetic resonance imaging (MRI), 14-3-3 
protein measurement, genetic analysis, and neuropathological assessment). The findings of 
descriptive statistical analysis were compared with data from the biomarker literature. 
 
2. Patients, materials, and methods 
2.1 Sample collection and the work-up of clinical data 
All patients with relatively rapidly progressive dementia with suspected CJD who underwent a 
lumbar puncture since 2004 at the Department of Neurology, University of Szeged were 
enrolled to this retrospective study, following the approval of the local Ethical Committee of 
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the University of Szeged (46/2014), adhering to the tenets of the most recent revision of the 
Declaration of Helsinki. For the clinical diagnosis of CJD according to the criteria10,11, in 
addition to the progressive dementia, the presence of the following 4 clinical features were 
assessed: myoclonus, visual or cerebellar disturbance, pyramidal/extrapyramidal dysfunction, 
and akinetic mutism. Furthermore, to be able to distinguish between possible and probable CJD, 
the available EEG and MRI findings were analyzed as well looking for periodic sharp wave 
complexes and high signal abnormalities in caudate nucleus and putamen or at least two cortical 
regions (temporal-parietal-occipital) either in DWI or FLAIR29, respectively, along with the 
qualitative determination of CSF 14-3-3 protein with Western blot technique. The diagnosis of 
definite CJD was based on post-mortem neuropathological findings. The test results were 
supplemented with the data of genetic analysis (either PRNP gene mutation or codon 129 
polymorphism) where available as well, which examinations together with the 
determination of 14-3-3 protein were carried out at the Prion Disease and Neuropathology 
Reference Center, Semmelweis University, Budapest, Hungary, and Institute of 
Neurology, Medical University of Vienna, Vienna, Austria. Patients with relatively rapidly 
progressive dementia who did not meet the diagnostic criteria for CJD were designated as non-
prion rapidly progressive dementia (npRPD). 
 
2.2 Determination of CSF total tau, phosphorylated tau, and beta-amyloid levels 
Following the lumbar puncture, the CSF samples were centrifuged at 8.000 RPM for 10 min. 
The supernatants were stored in sterile polypropylene tubes in −80°C until use, distributed into 
aliquots to avoid repeated freeze–thaw cycles. We utilized commercially available ELISA kits 
(Innogenetics N.V., now Fujirebio Europe N.V., Ghent, Belgium) for the quantitative 
determination of A1-42, tTau, and pTau (phosphorylated at threonine 181) levels according 
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to the manufacturers’ instruction, as described previously30. Briefly, all samples and standards 
were run in duplicates, the optical density values were detected at 450/560 nm with a plate 
reader (Awareness Technology Inc., Palm City, FL, USA) and the respective concentrations 
were read from the standard curves fitted by Sigmaplot 10.0 software (Systat Software Inc., 
Richmond, CA, USA). The lower limit of detection of the assays was 87, 87 and 15 pg/ml for 
A1-42, tTau, and pTau, respectively. The normal values provided by the reference manual are 
presented in the footnotes of Table 1. Where the measured values of tTau exceeded that of the 
highest standard, the actual highest standard values were given. Values were accepted if the 
respective coefficients of variation were less than 15%. 
Our laboratory is approved for the diagnostic analyses of tTau, pTau, and A1-42, by the applied 
kits, for which we could use samples running in the ‘Alzheimer's Association QC program for 
CSF biomarkers’ as quality control samples to rule out analytical bias. 
 
2.3 Statistical analyses 
The sensitivity (i.e., the number of CJD patients with alteration in the observed parameter / (the 
number of CJD patients with alteration in the observed parameter + the number of CJD patients 
without alteration in the observed parameter)) and specificity (the number of npRPD patients 
without alteration in the observed parameter / (the number of npRPD patients without alteration 
in the observed parameter + the number of npRPD patients with alteration in the observed 
parameter)) values were calculated for all the laboratory biomarkers, and for the presence of 
characteristic findings on the EEG and MRI as well. Alteration in a chemical biomarker was 
considered if the CSF level was higher than the established cut-off for tTau and pTau and lower 
than that for A1-42, whereas CSF 14-3-3 was considered altered when it was positive. The cut-
off values used and the method of their calculation are presented in the footnotes of Table 2. A 
10 
 
descriptive statistical analysis was carried out for the sensitivity and specificity values found in 
the scientific literature for all the above-mentioned and some other biomarkers. 
 
3. Results 
The clinical data (in light of the diagnostic criteria of CJD), the test results, and the autopsy 
findings (where applicable) of patients presenting with relatively rapidly progressive dementia 
who underwent lumbar puncture in the period of 2004-2017 at the University of Szeged, 
Department of Neurology are demonstrated in Table 1. The proportion of genetically 
determined CJD among CJD cases that underwent genetic analysis was remarkably high (6/7), 
which is in line with previous data reporting the gCJD form to predominate in this geographical 
area31,32, contrasting with international data7. This is most probably not merely attributable to 
selection bias secondary to an influence by a positive family history, as this incidence is 
substantially high even if related to all consecutive CJD cases identified (6/12). Although, due 
to the limited number of cases in this preliminary study, a receiver operating characteristic 
(ROC) curve analysis cannot be carried out, the respective crude sensitivity and specificity 
values could be easily calculated by using the equations above, and these data are presented in 
Table 2. The specificity for CJD was found to be as surprisingly high as 100% in the cases of 
both the PSWCs in EEG and the characteristic alterations in MRI, but the sensitivity was only 
fair (75% and 80%, respectively). Among CSF biomarkers, only 14-3-3 and tTau provided 
100% sensitivity (if mean + 1 SD of the reference values was applied as cut-off for tTau). 
However, the specificity of 14-3-3-positivity was considerably poor (40%), whereas that of 
tTau elevation was found to be fair (71%). If cut-off values were changed to > 1200 pg/ml for 
tTau (consistent with many of the studies in the literature), both good sensitivity (83%) and 
specificity (86%) values could be achieved. Due to the very limited number of cases where both 
measurement data were available, only an approximation could be carried out on the utility of 
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their combined use, providing a sensitivity of 87.5% and a specificity of 80%. The sensitivity 
values for pTau (25% in the case of both cut-off values) and A1-42 (50% and 17%, respectively) 
remained considerably low irrespective of the application of the upper quartile and the mean - 
1 SD of the reference values as cut-offs, respectively, or > 60 pg/ml and < 400 pg/ml values 
(consistent with many of the studies in the literature), respectively. Surprisingly, the specificity 
values for pTau were found to be good (86% in both cases), irrespective of the applied cut-off 
values. However, the specificity values for A1-42 remained considerably low, irrespective of 
the applied cut-off values as well (29% and 57%, respectively). 
 
4. Discussion 
CJD is a rapidly progressive, fatal neurological disorder, where only autopsy provides definite 
diagnosis. Accordingly, there is a special need for fine diagnostic tools in live patients to 
achieve accurate diagnosis as early as possible. In addition to the prognostic importance of the 
early diagnosis for the patients and their relatives, the possibility of disease transmission may 
raise hygienic considerations as well33, despite the fact that CJD cannot be transmitted through 
direct contact or airborne spread34. Accordingly, only the standard precautions are to be 
complied with by the caregivers. However, in case of iatrogenic and variant forms, the direct 
implantation or transplantation of materials of human-origin or the consumption of infected 
bovine meat may result in disease transmission35. 
As mentioned above, at present, the definite diagnosis of CJD can only be established by 
confirming pathological prion protein deposition in the brain36. However, the probabilistic 
clinical diagnosis can be supported by the presence of PSWCs in EEG and/or abnormal signal 
changes on DWI or FLAIR MRI evaluated by a qualified neuroradiologist, trained to detect the 
characteristic signs for CJD. Both methods provide good specificity (74–100%1,12,37,38 and 83–
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100%29,37,39, respectively), confirmed by the results of the current study as well (Table 2), but 
the sensitivity values are often only fair (32–66%1,12,37,38 and 62.9–100%37,39, respectively). 
Accordingly, the additional utility of several chemical biomarkers of neuronal damage were 
assessed to achieve a more precise diagnosis. The most commonly used chemical biomarker in 
CJD is the 14-3-3 protein13,14,16, with sensitivity and specificity values ranging between 50% 
and 100% and between 40% and 97%, respectively13,14,16,40. Keeping in mind the heterogeneous 
nature of literature data, mainly as regards the composition of control groups, when studies 
using npRPDs as controls were selected to decrease the heterogeneity, the values remained 
almost the same. Surprisingly, the results of the current study demonstrated an opposite 
pattern of sensitivity and specificity values, i.e., excellent sensitivity and poor specificity. 
On the one hand, the sensitivity values may be influenced by the presence of PRNP gene 
mutation or codon 129 polymorphism16, which may have a special relevance to the current 
study as well due to the predominance of gCJD cases (E200K mutation) and MM genotype 
at codon 129. Although the presence of E200K mutation may slightly decrease the 
sensitivity, the MM genotype probably counteracts it. However, in light of the low number 
of cases, this hypothesis is at most speculative. The poor specificity of 14-3-3 may be the 
result of the small number of patients in the cohort with npRPD, including disorders with 
considerable tissue damage, such as carcinomatous meningitis or ischemic stroke, both of 
which can be accompanied with elevated CSF 14-3-3 levels41,42. However, CSF cytology or 
the assessment of MRI findings by a qualified neuroradiologist, respectively, may help in 
the exclusion of these entities behind the clinical picture of rapidly progressive dementia. 
The second most commonly applied biomarker is the tTau protein14,16,23, which is also 
considered to have a possible diagnostic value in light of its relatively high sensitivity (ranging 
between 75% and 94%) and specificity (ranging between 84% and 97%)14. With regard to 
the current study, if we applied the mean + 1 SD of the control values provided by the 
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manufacturer as cut-off level, a considerably high (100%) sensitivity value was achieved but 
the specificity remained only fair (71%). Although the limited number of samples did not allow 
the use of ROC analysis, the increase of the cut-off value to 1200 pg/ml, the cut-off reported in 
the majority of literature, resulted in the increase of specificity (86%) with a consequent 
decrease of sensitivity (83%), but in that case, both of them could be considered to be good. 
The utility of the combined use of these 2 biomarkers was assessed as well in some studies, 
resulting in a slightly decreased sensitivity (49–92%43,44) but a considerable increase in 
specificity (82–98%43,44). Due to the reduced number of data for this analysis, the current study 
could not replicate this change. The statistical comparison of sensitivity and specificity values 
obtained in these complex studies demonstrated a significantly (p  0.001) better specificity for 
tTau than 14-3-340. 
Less data are available about the utility of other chemical biomarkers in the diagnostic work-
up of CJD. The assessment of S100B14, NSE14, and PrP protein19,45 for that purpose provided 
sensitivity values ranging between 65% and 82%, 73% and 90% and 77% and 82.4% 
respectively, with specificity values ranging between 76% and 93%, 79% and 95% and 82.1% 
and 100% respectively. In light of these ranges, the diagnostic utility of these chemical 
biomarkers seemingly does not exceed those of 14-3-3 and tTau proteins; however, the 
considerably high specificity values draw attention to more and more widespread application 
of the determination of PrP protein. 
The availability of literature data is limited with regard to the application of A1-42 peptide and 
pTau protein as chemical biomarkers in CJD, and it was proposed that these substances alone 
are not suitable as diagnostic markers for CJD, as their concentration values overlap with other 
neurological diseases24,46. However, they may be relevant for the assessment of other 
neurodegenerative conditions OR concomitant pathologies in CJD, such as AD. In line 
with these findings, the present study demonstrated poor sensitivity (50% or 17% if mean - 1 
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SD of the reference values provided by the manufacturer or 400 pg/ml levels were applied as 
cut-offs, respectively) and specificity values (29% or 57% if mean - 1 SD of the reference values 
provided by the manufacturer or 400 pg/ml levels were applied as cut-offs, respectively) for 
A1-42 peptide.  
Although the current study showed good specificity values for pTau (86%, either the cut-off 
value was calculated as the upper quartile of the reference values according to the manual or a 
cut-off value of > 60 pg/ml was applied) similarly to those reported in the literature (ranging 
between 58% and 95%14), the sensitivity values remained considerably poor (25%, either the 
cut-off value was calculated as the upper quartile of the reference values according to the 
manual or a cut-off value of > 60 pg/ml was applied), in line with literature data ranging 
between 19.35% and 93%14,47. Accordingly, despite this good specificity values for pTau 
(phosphorylated at threonine 181), a recent neuropathological study suggest that it does 
not reliably reflect the tau pathology in CJD brains48. This is because pTau epitopes may 
vary considerably even within the same disease and that antibodies against this particular 
pTau epitope that is in fact assessed in most of the applied assays label the smallest amount 
of pathological tau alterations in post-mortem brains4,48. 
Beside the above chemical biomarkers, some promising novel ones have been recently reported 
as well, including NF-L and pNF-H, with considerably high sensitivity and specificity 
values18,23. Some recent studies15,26 have reported larger than 95% sensitivity and specificity 
values for α-synuclein when comparing sCJD with the control group. 
It can be concluded that despite the low number of cases, the present preliminary study 
replicated well the results of previous studies with large subject numbers, except for the poor 
specificity value for 14-3-3. In light of literature data, probably the measurement of 14-3-3 
and tTau protein levels are the most widely used approaches to detect the characteristic 
pronounced neuronal damage in CJD. Recently, several attempts have been made by the 
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application of novel chemical biomarkers to increase the sensitivity and specificity for the 
diagnosis of CJD; however, except for the excellent specificity values for PrP, neither of them 
provided reliably high values near 100%. Accordingly, the combination of these tests may yield 
the best diagnostic value, keeping in mind the availability and preferably low cost of the 
methods as well. 
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7. Figure legend 
Fig. 1. Some major physiological functions of certain chemical biomarkers, most frequently 
assessed in Creutzfeldt-Jakob disease 
